Experimental HIV therapy aims to free patients from daily pills
NCT ID NCT06430905
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests two experimental vaccines, HB-502 and HB-501, designed to teach the immune system to recognize and attack HIV. The study includes 30 people with HIV who are already on suppressive antiretroviral therapy. Participants receive injections every 8 weeks for 24 weeks, followed by 24 weeks of monitoring to check safety and immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HB-502 and HB-501 (arenavirus-based vector therapy)
- What this could lead to
- If successful, this could point toward a way to control HIV without lifelong daily medication, potentially allowing people to stop antiretroviral therapy.
- What could go wrong
- This is a very early phase 1 trial with only 30 participants, focused on safety. It may not show strong immune responses, and the study has already been terminated, so results may be limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconness Medical Center (BIDMC)
Boston, Massachusetts, 02215, United States
-
Brigham and Women´s Hospital
Boston, Massachusetts, 02115, United States
-
Orlando Immunology Center (OIC)
Orlando, Florida, 32803, United States
-
Perelman Center for Advanced Medicine at the Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
The Hope Clinic at Emory University
Decatur, Georgia, 30030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.